

Kallikrein 8 Antibody (N-term) Blocking peptide
Synthetic peptide
Catalog # BP6327a**Specification**

Kallikrein 8 Antibody (N-term) Blocking peptide - Product InformationPrimary Accession [O60259](#)**Kallikrein 8 Antibody (N-term) Blocking peptide - Additional Information****Gene ID** 11202**Other Names**

Kallikrein-8, hK8, Neuropsin, NP, Ovasin, Serine protease 19, Serine protease TADG-14, Tumor-associated differentially expressed gene 14 protein, KLK8, NRPN, PRSS19, TADG14

Target/Specificity

The synthetic peptide sequence used to generate the antibody [AP6327a](/product/products/AP6327a) was selected from the N-term region of human KLK8. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

Kallikrein 8 Antibody (N-term) Blocking peptide - Protein Information**Name** KLK8**Synonyms** NRPN, PRSS19, TADG14**Function**

Serine protease which is capable of degrading a number of proteins such as casein, fibrinogen, kininogen, fibronectin and collagen type IV. Also cleaves L1CAM in response to increased neural activity. Induces neurite outgrowth and fasciculation of cultured hippocampal neurons. Plays a role in the formation and maturation of orphan and small synaptic boutons in the Schaffer-collateral pathway, regulates Schaffer-collateral long-term potentiation in the hippocampus and is required for memory acquisition and synaptic plasticity. Involved in skin desquamation and keratinocyte proliferation. Plays a role in the secondary phase of pathogenesis following spinal cord injury.

Cellular Location

Secreted. Cytoplasm. Note=Shows a cytoplasmic distribution in the keratinocytes

Tissue Location

Isoform 1 is predominantly expressed in the pancreas. Isoform 2 is expressed in adult brain and hippocampus. Isoform 1 and isoform 2 are found in fetal brain and placenta. Detected in salivary gland, uterus, thymus, breast, testis and kidney but not in spleen, liver, lung or normal ovarian tissue. Displays an 11.5-fold increase in Alzheimer disease hippocampus compared to controls and is overexpressed in some ovarian carcinomas. Expressed at low levels in normal skin while high levels are found in psoriasis vulgaris, seborrheic keratosis, lichen planus and squamous cell carcinoma skin samples. Expressed in the keratinocytes.

Kallikrein 8 Antibody (N-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

Kallikrein 8 Antibody (N-term) Blocking peptide - Images

Kallikrein 8 Antibody (N-term) Blocking peptide - Background

Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. There are four different isoforms of KLK8, exhibiting distinct patterns of expression that suggest roles in brain plasticity and ovarian cancer.

Kallikrein 8 Antibody (N-term) Blocking peptide - References

Li, Y., et al., Mol. Biol. Evol. 21(11):2111-2115 (2004). Shigemasa, K., et al., Oncol. Rep. 11(6):1153-1159 (2004). Cane, S., et al., Am. J. Obstet. Gynecol. 190(1):60-66 (2004). Clark, H.F., et al., Genome Res. 13(10):2265-2270 (2003). Magklara, A., et al., Clin. Cancer Res. 7(4):806-811 (2001).